Sign inJoin waitlistJoin the waitlist

Davendra Sohal

Associate Director for Clinical Research · University of Cincinnati Medical Center Inc.

Credentials: · · · · ·

History

GI Cancers Center of Excellence · University of Cincinnati Medical Center Inc.
Present
University of Cincinnati Medical Center Inc.
Present

Medical Oncology
Internal Medicine
University of Alabama at Birmingham (Public Health
ALL INDIA INST OF MED SCI, ANSARI NAGAR, NEW DELHI, DELHI

Research

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Journal of Clinical Oncology · 2020 · 478 citations
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
The Lancet Oncology · 2020 · 455 citations

Alok Khorana
16 papers
Syed Ahmad
16 papers
Philip Philip
11 papers
Amit Verma
9 papers
Olugbenga Olowokure
9 papers
Sameer Patel
9 papers
Andrew Hendifar
8 papers
Emil Lou
8 papers
Greg Wilson
8 papers
Jordan Kharofa
8 papers
Benjamin Weinberg
7 papers
Heinz-Josef Lenz
7 papers

Grants

NCI-Sponsored Leadership Focused on Clinical Trial Enrollment
National Cancer Institute · R50
Contact PI · $240.3K · University of Cincinnati
2026–2031
Phase I/II Clinical Evaluation of ABTL0812, a Novel PI3K/Akt/mTOR Inhibitor, with a Unique Mechanism of Action Inpancreatic Cancer (Protocol Sent on 20th June 2019 as an Amendment of the IND 137394)
Food and Drug Administration · R01
Contact PI · $1.8M · University of Cincinnati
2020–2025

Clinical trials

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Principal investigator · Terminated · Phase 2
University of Cincinnati
2021–2024
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
Principal investigator · Active not recruiting · Phase 2
University of Cincinnati
2021–2027
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Principal investigator · Terminated · Phase 2
Case Comprehensive Cancer Center
2016–2018
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Principal investigator · Completed · Phase 2
SWOG Cancer Research Network
2016–2022